Co-delivery of quercetin and caffeic-acid phenethyl ester by polymeric nanoparticles for improved antitumor efficacy in colon cancer cells
This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells. QuCaNPs were synthesised using single-emulsion (o/w) solvent evapo...
Saved in:
| Published in | Journal of microencapsulation Vol. 38; no. 6; pp. 381 - 393 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
Taylor & Francis
18.08.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0265-2048 1464-5246 1464-5246 |
| DOI | 10.1080/02652048.2021.1948623 |
Cover
Loading…
| Abstract | This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells.
QuCaNPs were synthesised using single-emulsion (o/w) solvent evaporation method. Particle size, zeta potential, polydispersity index, in vitro release profile, and surface morphology of QuCaNPs were determined. Cytotoxicity, anti-migration, anti-proliferation and apoptotic activities of QuCaNPs were studied.
Mean diameter of QuCaNP was 237.8 ± 9.670 nm, with a polydispersity index (PDI) of 0.340 ± 0.027. Encapsulation efficiency was 74.28% (quercetin) and 65.24% (CAPE). Particle size and drug content of QuCaNP remained stable for 30 days at −20 °C. The half-maximal inhibitory concentration (IC
50
) values of QuCaNP-treated HT-29 cells were calculated as 11.2 µg/mL (24 h) and 8.2 µg/mL (48 h). QuCaNP treatment increased mRNA levels of caspase-3 (2.38 fold) and caspase-9 (2-fold) and expressions of key proteins in the intrinsic apoptosis pathway in HT-29 cells.
Overall, our results demonstrated QuCaNPs exhibits improved anti-cancer activity on HT-29 cells. |
|---|---|
| AbstractList | This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells.
QuCaNPs were synthesised using single-emulsion (o/w) solvent evaporation method. Particle size, zeta potential, polydispersity index, in vitro release profile, and surface morphology of QuCaNPs were determined. Cytotoxicity, anti-migration, anti-proliferation and apoptotic activities of QuCaNPs were studied.
Mean diameter of QuCaNP was 237.8 ± 9.670 nm, with a polydispersity index (PDI) of 0.340 ± 0.027. Encapsulation efficiency was 74.28% (quercetin) and 65.24% (CAPE). Particle size and drug content of QuCaNP remained stable for 30 days at −20 °C. The half-maximal inhibitory concentration (IC
50
) values of QuCaNP-treated HT-29 cells were calculated as 11.2 µg/mL (24 h) and 8.2 µg/mL (48 h). QuCaNP treatment increased mRNA levels of caspase-3 (2.38 fold) and caspase-9 (2-fold) and expressions of key proteins in the intrinsic apoptosis pathway in HT-29 cells.
Overall, our results demonstrated QuCaNPs exhibits improved anti-cancer activity on HT-29 cells. This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells.AIMThis study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells.QuCaNPs were synthesised using single-emulsion (o/w) solvent evaporation method. Particle size, zeta potential, polydispersity index, in vitro release profile, and surface morphology of QuCaNPs were determined. Cytotoxicity, anti-migration, anti-proliferation and apoptotic activities of QuCaNPs were studied.METHODSQuCaNPs were synthesised using single-emulsion (o/w) solvent evaporation method. Particle size, zeta potential, polydispersity index, in vitro release profile, and surface morphology of QuCaNPs were determined. Cytotoxicity, anti-migration, anti-proliferation and apoptotic activities of QuCaNPs were studied.Mean diameter of QuCaNP was 237.8 ± 9.670 nm, with a polydispersity index (PDI) of 0.340 ± 0.027. Encapsulation efficiency was 74.28% (quercetin) and 65.24% (CAPE). Particle size and drug content of QuCaNP remained stable for 30 days at -20 °C. The half-maximal inhibitory concentration (IC50) values of QuCaNP-treated HT-29 cells were calculated as 11.2 µg/mL (24 h) and 8.2 µg/mL (48 h). QuCaNP treatment increased mRNA levels of caspase-3 (2.38 fold) and caspase-9 (2-fold) and expressions of key proteins in the intrinsic apoptosis pathway in HT-29 cells.RESULTSMean diameter of QuCaNP was 237.8 ± 9.670 nm, with a polydispersity index (PDI) of 0.340 ± 0.027. Encapsulation efficiency was 74.28% (quercetin) and 65.24% (CAPE). Particle size and drug content of QuCaNP remained stable for 30 days at -20 °C. The half-maximal inhibitory concentration (IC50) values of QuCaNP-treated HT-29 cells were calculated as 11.2 µg/mL (24 h) and 8.2 µg/mL (48 h). QuCaNP treatment increased mRNA levels of caspase-3 (2.38 fold) and caspase-9 (2-fold) and expressions of key proteins in the intrinsic apoptosis pathway in HT-29 cells.Overall, our results demonstrated QuCaNPs exhibits improved anti-cancer activity on HT-29 cells.CONCLUSIONOverall, our results demonstrated QuCaNPs exhibits improved anti-cancer activity on HT-29 cells. This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and investigate their anti-cancer activity on human colorectal carcinoma HT-29 cells. QuCaNPs were synthesised using single-emulsion (o/w) solvent evaporation method. Particle size, zeta potential, polydispersity index, release profile, and surface morphology of QuCaNPs were determined. Cytotoxicity, anti-migration, anti-proliferation and apoptotic activities of QuCaNPs were studied. Mean diameter of QuCaNP was 237.8 ± 9.670 nm, with a polydispersity index (PDI) of 0.340 ± 0.027. Encapsulation efficiency was 74.28% (quercetin) and 65.24% (CAPE). Particle size and drug content of QuCaNP remained stable for 30 days at -20 °C. The half-maximal inhibitory concentration (IC ) values of QuCaNP-treated HT-29 cells were calculated as 11.2 µg/mL (24 h) and 8.2 µg/mL (48 h). QuCaNP treatment increased mRNA levels of caspase-3 (2.38 fold) and caspase-9 (2-fold) and expressions of key proteins in the intrinsic apoptosis pathway in HT-29 cells. Overall, our results demonstrated QuCaNPs exhibits improved anti-cancer activity on HT-29 cells. |
| Author | Colpan, Reyhan Dilsu Erdemir, Aysegul |
| Author_xml | – sequence: 1 givenname: Reyhan Dilsu orcidid: 0000-0002-4179-624X surname: Colpan fullname: Colpan, Reyhan Dilsu organization: Department of Molecular Biology and Genetics, Faculty of Arts and Science, Yildiz Technical University – sequence: 2 givenname: Aysegul orcidid: 0000-0002-6099-4903 surname: Erdemir fullname: Erdemir, Aysegul organization: Department of Molecular Biology and Genetics, Faculty of Arts and Science, Yildiz Technical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34189998$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcGOFCEURYkZ4_SMfoKGpZtqgaJoiBtNR51JJnGja0JRjwyGghboMfUL89VS6R4XLnQDgZx78969V-gipggIvaZkS4kk7wgTAyNcbhlhdEsVl4L1z9CGcsG7gXFxgTYr063QJboq5QchZFCSvUCXPadSKSU36HGfugmCf4C84OTwzyNkC9VHbOKErXEOvO2M9RM-3EOEer8EDKVCxuOCDyksM2RvcTQxHUyu3gYo2KWM_XzI6QGmZlR9Pc7tC5zz1tgFN3ubQmqnibZZWQihvETPnQkFXp3va_T986dv-5vu7uuX2_3Hu872QtRuJ9mgRiJoP-4Eoe01SttTNRiY6CCMFDtieD8BsxYYd4aIEdSglJN2stT21-jtybfN19YtVc--rBOYCOlYNBu4UJJwyhv65owexxkmfch-NnnRT_k1YDgBNqdSMrg_CCV67Uk_9aTXnvS5p6Z7_5fO-mqqT7Fm48N_1R9Oah9b0rP5lXKYdDVLSNnlFqkvuv-3xW9V161v |
| CitedBy_id | crossref_primary_10_1016_j_jddst_2024_106255 crossref_primary_10_1016_j_fct_2021_112770 crossref_primary_10_3390_pharmaceutics15112566 crossref_primary_10_2174_0113894501292466240627050638 crossref_primary_10_3390_ma14226812 crossref_primary_10_1002_btm2_70006 crossref_primary_10_1080_10942912_2023_2252619 crossref_primary_10_3389_fnut_2022_999752 crossref_primary_10_1016_j_jddst_2023_104859 crossref_primary_10_1016_j_ijpharm_2024_124047 crossref_primary_10_1002_cam4_7010 crossref_primary_10_1002_pat_5874 crossref_primary_10_1016_j_jddst_2022_104112 crossref_primary_10_1016_j_foodchem_2022_134409 crossref_primary_10_1007_s10876_024_02757_z crossref_primary_10_1016_j_ejmcr_2024_100137 crossref_primary_10_3390_antiox12081500 crossref_primary_10_3390_ijms222111669 crossref_primary_10_3389_fphar_2024_1325196 crossref_primary_10_1016_j_lwt_2023_115186 crossref_primary_10_1016_j_biopha_2023_115283 crossref_primary_10_1021_acsomega_3c07643 crossref_primary_10_1016_j_matdes_2024_112777 crossref_primary_10_1080_10408398_2022_2106471 crossref_primary_10_2174_0113892010242028231002075512 crossref_primary_10_2174_1570180820666230613152134 crossref_primary_10_3390_app12199479 crossref_primary_10_1016_j_foodres_2025_116208 crossref_primary_10_1088_2043_6262_acedaa crossref_primary_10_1016_j_procbio_2023_09_016 crossref_primary_10_1016_j_ijbiomac_2023_124508 crossref_primary_10_3390_pharmaceutics16060761 crossref_primary_10_1080_10408398_2022_2036095 |
| Cites_doi | 10.1007/s11434-016-1182-z 10.3892/mmr.2016.5818 10.1016/j.jconrel.2015.08.050 10.1007/s13205-013-0117-5 10.1080/10837450.2020.1740933 10.2174/187221112802652633 10.1136/gutjnl-2015-310912 10.1038/s41598-016-0028-x 10.1042/BJ20070617 10.3390/nu8090552 10.3892/ijo.2017.3886 10.1371/journal.pone.0099631 10.1002/jps.24278 10.1016/j.jconrel.2014.03.016 10.1159/000480528 10.1016/j.jddst.2020.102107 10.1016/j.bbrc.2018.04.174 10.1006/meth.2001.1262 10.3390/pharmaceutics11080401 10.1016/j.phymed.2018.09.224 10.3390/ijms20051199 10.1016/S0168-3659(02)00320-6 10.3390/molecules22091554 10.1146/annurev-physiol-021119-034627 10.1016/j.etap.2011.07.003 10.1007/s11095-008-9800-3 10.1039/C6PY01872F 10.1088/1361-6528/ab6ab9 10.15171/apb.2019.024 10.1007/s10103-020-02964-w 10.1016/S0168-3659(97)00241-1 10.1016/j.ijpharm.2004.08.008 10.7150/jca.15170 10.3322/caac.21551 10.1016/j.jfda.2014.06.001 10.1088/0957-4484/27/2/025103 10.1002/adfm.201401076 10.3390/molecules21010108 10.1080/21691401.2018.1556213 10.1093/jn/136.11.2715 10.1007/s12645-012-0027-y 10.1155/2012/145380 10.1063/1.4962992 10.1016/j.jddst.2020.101928 10.1016/j.ijpharm.2017.03.040 10.1016/j.bbagen.2016.07.001 10.1016/j.bmc.2013.08.057 |
| ContentType | Journal Article |
| Copyright | 2021 Informa UK Limited, trading as Taylor & Francis Group 2021 |
| Copyright_xml | – notice: 2021 Informa UK Limited, trading as Taylor & Francis Group 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1080/02652048.2021.1948623 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1464-5246 |
| EndPage | 393 |
| ExternalDocumentID | 34189998 10_1080_02652048_2021_1948623 1948623 |
| Genre | Research Article Journal Article |
| GroupedDBID | --- 00X 03L 0BK 0R~ 29L 36B 4.4 53G 5GY AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABXYU ACENM ACGEJ ACGFS ACIEZ ACUHS ADCVX ADNWM ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EAP EAS EBC EBD EBS EBX EHN EMB EMK EPL EPT ESX F5P H13 HZ~ KRBQP KWAYT KYCEM LJTGL M4Z O9- P2P Q~Q RNANH RVRKI TBQAZ TERGH TFDNU TFL TFW TUROJ TUS UEQFS UHWXJ V1S ~1N AAGDL AAYXX ABWVI ADYSH AFRVT AMPGV CITATION EMOBN SV3 5VS AALIY AAORF AAPXX ABWCV ABZEW ACKZS ADFOM ADFZZ AEIIZ AFLEI AJVHN AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE DWTOO ECM EIF EJD JENTW M44 NPM NUSFT OVD QQXMO TEORI 7X8 |
| ID | FETCH-LOGICAL-c366t-78259b0613b7601825b8c3195aed156a8670a43de2cce24fa06be9599f8cdc1c3 |
| ISSN | 0265-2048 1464-5246 |
| IngestDate | Fri Jul 11 05:25:17 EDT 2025 Wed Feb 19 02:28:33 EST 2025 Tue Jul 01 02:53:42 EDT 2025 Thu Apr 24 23:44:08 EDT 2025 Wed Dec 25 09:07:34 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | nanoparticle caffeic-acid phenethyl ester anti-cancer colon cancer Quercetin |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c366t-78259b0613b7601825b8c3195aed156a8670a43de2cce24fa06be9599f8cdc1c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6099-4903 0000-0002-4179-624X |
| PMID | 34189998 |
| PQID | 2546980414 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2546980414 informaworld_taylorfrancis_310_1080_02652048_2021_1948623 crossref_primary_10_1080_02652048_2021_1948623 crossref_citationtrail_10_1080_02652048_2021_1948623 pubmed_primary_34189998 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-18 |
| PublicationDateYYYYMMDD | 2021-08-18 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of microencapsulation |
| PublicationTitleAlternate | J Microencapsul |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | CIT0030 CIT0032 CIT0031 CIT0034 CIT0033 Je Y.Y. (CIT0019) 2005; 15 CIT0036 CIT0035 CIT0038 CIT0039 CIT0041 CIT0040 CIT0043 CIT0042 CIT0001 CIT0044 CIT0003 CIT0047 CIT0002 CIT0046 CIT0005 CIT0049 CIT0004 CIT0048 CIT0007 CIT0006 CIT0009 CIT0008 CIT0050 CIT0010 CIT0012 CIT0011 Leigh Ackland M. (CIT0025) 2005; 19 CIT0014 CIT0013 CIT0016 CIT0015 Tang H. (CIT0045) 2017; 7 CIT0018 CIT0017 Prabhuraj R.S. (CIT0037) 2020; 27 CIT0021 CIT0020 CIT0023 CIT0022 CIT0024 CIT0027 CIT0026 CIT0029 CIT0028 |
| References_xml | – ident: CIT0036 doi: 10.1007/s11434-016-1182-z – ident: CIT0049 doi: 10.3892/mmr.2016.5818 – ident: CIT0011 doi: 10.1016/j.jconrel.2015.08.050 – ident: CIT0005 doi: 10.1007/s13205-013-0117-5 – ident: CIT0014 doi: 10.1080/10837450.2020.1740933 – ident: CIT0016 doi: 10.2174/187221112802652633 – ident: CIT0004 doi: 10.1136/gutjnl-2015-310912 – volume: 7 start-page: 1 issue: 1 year: 2017 ident: CIT0045 publication-title: Scientific reports doi: 10.1038/s41598-016-0028-x – ident: CIT0046 doi: 10.1042/BJ20070617 – ident: CIT0033 doi: 10.3390/nu8090552 – ident: CIT0039 doi: 10.3892/ijo.2017.3886 – ident: CIT0008 doi: 10.1371/journal.pone.0099631 – ident: CIT0024 doi: 10.1002/jps.24278 – ident: CIT0050 doi: 10.1016/j.jconrel.2014.03.016 – ident: CIT0023 doi: 10.1159/000480528 – ident: CIT0002 doi: 10.1016/j.jddst.2020.102107 – ident: CIT0001 doi: 10.1016/j.bbrc.2018.04.174 – ident: CIT0028 doi: 10.1006/meth.2001.1262 – ident: CIT0038 doi: 10.3390/pharmaceutics11080401 – ident: CIT0044 doi: 10.1016/j.phymed.2018.09.224 – ident: CIT0007 doi: 10.3390/ijms20051199 – ident: CIT0030 doi: 10.1016/S0168-3659(02)00320-6 – ident: CIT0020 doi: 10.3390/molecules22091554 – ident: CIT0006 doi: 10.1146/annurev-physiol-021119-034627 – ident: CIT0042 doi: 10.1016/j.etap.2011.07.003 – ident: CIT0047 doi: 10.1007/s11095-008-9800-3 – ident: CIT0022 doi: 10.1039/C6PY01872F – ident: CIT0012 doi: 10.1088/1361-6528/ab6ab9 – ident: CIT0018 doi: 10.15171/apb.2019.024 – volume: 27 start-page: 1 issue: 5 year: 2020 ident: CIT0037 publication-title: Journal of polymer research – ident: CIT0010 doi: 10.1007/s10103-020-02964-w – volume: 15 start-page: 279 issue: 4 year: 2005 ident: CIT0019 publication-title: Bio-Medical materials and engineering – ident: CIT0026 doi: 10.1016/S0168-3659(97)00241-1 – ident: CIT0021 doi: 10.1016/j.ijpharm.2004.08.008 – ident: CIT0048 doi: 10.7150/jca.15170 – ident: CIT0043 doi: 10.3322/caac.21551 – ident: CIT0031 doi: 10.1016/j.jfda.2014.06.001 – ident: CIT0003 doi: 10.1088/0957-4484/27/2/025103 – ident: CIT0029 doi: 10.1002/adfm.201401076 – ident: CIT0032 doi: 10.3390/molecules21010108 – ident: CIT0015 doi: 10.1080/21691401.2018.1556213 – ident: CIT0017 doi: 10.1093/jn/136.11.2715 – ident: CIT0034 doi: 10.1007/s12645-012-0027-y – volume: 19 start-page: 69 issue: 1 year: 2005 ident: CIT0025 publication-title: In vivo – ident: CIT0035 doi: 10.1155/2012/145380 – ident: CIT0009 doi: 10.1063/1.4962992 – ident: CIT0013 doi: 10.1016/j.jddst.2020.101928 – ident: CIT0027 doi: 10.1016/j.ijpharm.2017.03.040 – ident: CIT0041 doi: 10.1016/j.bbagen.2016.07.001 – ident: CIT0040 doi: 10.1016/j.bmc.2013.08.057 |
| SSID | ssj0005982 |
| Score | 2.4769933 |
| Snippet | This study aimed to synthesise quercetin- caffeic-acid phenethyl ester (CAPE)-co-loaded poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (QuCaNP) and... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 381 |
| SubjectTerms | anti-cancer caffeic-acid phenethyl ester colon cancer Colonic Neoplasms - drug therapy Esters Humans nanoparticle Nanoparticles Particle Size Polyglycolic Acid Quercetin Quercetin - pharmacology |
| Title | Co-delivery of quercetin and caffeic-acid phenethyl ester by polymeric nanoparticles for improved antitumor efficacy in colon cancer cells |
| URI | https://www.tandfonline.com/doi/abs/10.1080/02652048.2021.1948623 https://www.ncbi.nlm.nih.gov/pubmed/34189998 https://www.proquest.com/docview/2546980414 |
| Volume | 38 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBbbBEovpU0f2fSBCiWXjZe1Jb-OyaYhFFJy2EBuRtLK7YJjL_s4uD8hp_7kzkiy10sS0sfFrL3Ikj2fRjPyNzOEfI6lH8swiTyhZORxOPGSVEiPganMeD6SUYyxwxffovMr_vU6vO71fnVYS-uVHKqf98aV_ItU4RrIFaNk_0Ky7U3hAvwG-cIRJAzHP5LxuPKmukBmhflODip-oTCE2QariTzXMwWvZzYdIJNLg0yKgcmMgEbnvCpqS6QvRQmus2PIGd7hzGw1aEzjilSCG0wLjrkmsDa8Ia4XABqFgFkMcOt_-YCNe4N0P3hjAnzxYuub_7gq5u4TlK5_gJI5nRW2Boux7xdI2rd1tuul_u7Yi253IjDbrU6hmvi2O4VCOvotQILdyCbaHGqrf3nEwTd2u5JOQbOkA8SutmW22otbuJkttXhnTXAkSugNOxviKId-ysGVY5tFsKUmun-ekN0AHA9Q9bvHJ6cnZxvaUGoKkLWDb6LCMF_7fV1s2Ttb2XAf9mmMbTN5QZ47gdFjC4GXpKfLPfL0wtEu9sjhpU1wXh_RySZeb3lED-nlJvV5_YrcdhBJq5y2iKSASNpFJG0RSQ0iqaxpi0i6hUgKD0MbRNIWkbRBJIXbG0RSi0hqEPmaXJ19mYzPPVftw1OgGFYemKphKtG8lMjTgjOZKFggQqGnfhiJJIpHgrOpDpTSAc_FKJI6DdM0T9RU-Yq9ITtlVep9Qn3Gkxxc7UjGYF7n2DSIVeiLWDPNpOgT3sgkUy4VPlZkKTK_yZjrRJmhKDMnyj4Zts3mNhfMYw3SrsCzlZkNuZ0IGXuk7acGHRlofHxzotTVeplhBYsU04bxPnlrYdMOB2zSBFy-5OA_en5Hnm1m8nuys1qs9QewvFfyo5sMvwHuvtdE |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-delivery+of+quercetin+and+caffeic-acid+phenethyl+ester+by+polymeric+nanoparticles+for+improved+antitumor+efficacy+in+colon+cancer+cells&rft.jtitle=Journal+of+microencapsulation&rft.au=Colpan%2C+Reyhan+Dilsu&rft.au=Erdemir%2C+Aysegul&rft.date=2021-08-18&rft.pub=Taylor+%26+Francis&rft.issn=0265-2048&rft.eissn=1464-5246&rft.volume=38&rft.issue=6&rft.spage=381&rft.epage=393&rft_id=info:doi/10.1080%2F02652048.2021.1948623&rft.externalDocID=1948623 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-2048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-2048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-2048&client=summon |